CRA consultants assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. The evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.
CRA experts win prestigious 2026 Antitrust Writing Awards
The awards recognize outstanding scholarship and advocacy in antitrust law and economics. Christian Michel, a principal in the Antitrust & Competition...